Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
Ignite Proteomics (OTCQB: BACK) has announced a significant research collaboration with Inova Health to analyze tumor samples from late-stage cancer patients using their Reverse Phase Protein Array (RPPA) technology. The partnership will involve analyzing up to 600 tumor samples to generate biomarker data across various cancer-relevant drug target proteins.
The collaboration aims to help oncologists make more informed treatment decisions by providing actionable data to Inova's Molecular Tumor Board. The study will focus primarily on late-stage gastrointestinal cancers, analyzing protein targets including HER2, RET, MHC-II, EGFR, TROP2, AKT, and ERK. While financial terms weren't disclosed, this represents one of Ignite's most significant research services collaborations to date.
Ignite Proteomics (OTCQB: BACK) ha annunciato una collaborazione di ricerca significativa con Inova Health per analizzare campioni tumorali di pazienti con cancro in fase avanzata utilizzando la sua tecnologia Reverse Phase Protein Array (RPPA). La partnership prevede l'analisi di fino a 600 campioni tumorali per generare dati sui biomarcatori relativi a diversi proteine bersaglio rilevanti per la terapia oncologica.
L'obiettivo della collaborazione 猫 fornire dati utili al Molecular Tumor Board di Inova per supportare decisioni terapeutiche pi霉 informate. Lo studio si concentrer脿 principalmente sui tumori gastrointestinali in fase avanzata, analizzando proteine bersaglio come HER2, RET, MHC-II, EGFR, TROP2, AKT ed ERK. I termini finanziari non sono stati resi noti, ma si tratta di una delle collaborazioni di ricerca sui servizi pi霉 rilevanti nella storia di Ignite.
Ignite Proteomics (OTCQB: BACK) ha anunciado una colaboraci贸n de investigaci贸n significativa con Inova Health para analizar muestras tumorales de pacientes con c谩ncer en etapas avanzadas utilizando su tecnolog铆a Reverse Phase Protein Array (RPPA). La asociaci贸n implicar谩 el an谩lisis de hasta 600 muestras tumorales para generar datos de biomarcadores sobre diversas prote铆nas diana relevantes en oncolog铆a.
La colaboraci贸n busca proporcionar datos accionables al Molecular Tumor Board de Inova para ayudar a los onc贸logos a tomar decisiones de tratamiento m谩s informadas. El estudio se centrar谩 principalmente en los c谩nceres gastrointestinales en fase avanzada, analizando objetivos proteicos como HER2, RET, MHC-II, EGFR, TROP2, AKT y ERK. No se divulgaron los t茅rminos financieros, pero representa una de las colaboraciones de servicios de investigaci贸n m谩s relevantes hasta la fecha para Ignite.
Ignite Proteomics (OTCQB: BACK)臧赌 Inova Health鞕� 欷戩殧 鞐瓣惮 順戩梾鞚� 觳搓舶頃� 鞛愳偓鞚� Reverse Phase Protein Array(RPPA) 旮办垹搿� 歆勴枆靹� 鞎� 頇橃瀽鞚� 膦呾枒 靸橅攲鞚� 攵勳劃頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 韺岉姼雱堨嫮鞐愳劀電� 斓滊寑 600臧滌潣 膦呾枒 靸橅攲鞚� 攵勳劃頃� 鞎� 甏�霠� 旃橂 響滌爜 雼氨歆� 鞝勲皹鞐� 雽�頃� 氚旍澊鞓る旎� 雿办澊韯半ゼ 靸濎劚頃� 鞓堨爼鞛呺媹雼�.
順戩梾鞚� 氇╈爜鞚� Inova鞚� Molecular Tumor Board鞐� 鞁ろ枆 臧赌電ロ暅 雿办澊韯半ゼ 鞝滉车頃� 膦呾枒頃欖瀽霌れ澊 氤措嫟 鞝曤炒鞐� 旮半皹頃� 旃橂 瓴办爼鞚� 雮措Υ 靾� 鞛堧弰搿� 霃曤姅 瓴冹瀰雼堧嫟. 鞐瓣惮電� 欤茧 歆勴枆靹� 鞙勳灔甏�瓿� 鞎�鞚� 欷戩嫭鞙茧 歆勴枆霅橂┌ HER2, RET, MHC-II, EGFR, TROP2, AKT 氚� ERK 霌膘潣 雼氨歆� 響滌爜鞚� 攵勳劃頃╇媹雼�. 鞛爼 臁瓣贝鞚� 瓿店皽霅橃 鞎婌晿歆�毵�, 鞚措矆 瓯挫潃 Ignite臧赌 靾橅枆頃� 鞐瓣惮 靹滊箘鞀� 順戩梾 欷� 臧赌鞛� 欷戩殧頃� 靷 欷� 頃橂倶搿� 韽夑岸碾惄雼堧嫟.
Ignite Proteomics (OTCQB: BACK) a annonc茅 une importante collaboration de recherche avec Inova Health afin d'analyser des 茅chantillons tumoraux de patients atteints de cancers avanc茅s en utilisant sa technologie Reverse Phase Protein Array (RPPA). Le partenariat pr茅voit l'analyse de jusqu'脿 600 茅chantillons tumoraux pour g茅n茅rer des donn茅es de biomarqueurs sur divers prot茅ines cibles pertinentes en oncologie.
Cette collaboration vise 脿 fournir des donn茅es exploitables au Molecular Tumor Board d'Inova pour aider les oncologues 脿 prendre des d茅cisions th茅rapeutiques mieux inform茅es. L'茅tude portera principalement sur les cancers gastro-intestinaux avanc茅s, en analysant des cibles prot茅iques telles que HER2, RET, MHC-II, EGFR, TROP2, AKT et ERK. Les modalit茅s financi猫res n'ont pas 茅t茅 divulgu茅es, mais il s'agit de l'une des collaborations de services de recherche les plus importantes r茅alis茅es 脿 ce jour par Ignite.
Ignite Proteomics (OTCQB: BACK) hat eine bedeutende Forschungspartnerschaft mit Inova Health angek眉ndigt, um Tumorproben von Patienten mit fortgeschrittenem Krebs mittels ihrer Reverse Phase Protein Array (RPPA)-Technologie zu analysieren. Die Zusammenarbeit sieht die Analyse von bis zu 600 Tumorproben vor, um Biomarkerdaten zu verschiedenen f眉r die Krebstherapie relevanten Zielproteinen zu erzeugen.
Ziel der Kooperation ist es, dem Molecular Tumor Board von Inova verwertbare Daten zur Verf眉gung zu stellen, damit Onkologen fundiertere Behandlungsentscheidungen treffen k枚nnen. Die Studie konzentriert sich haupts盲chlich auf fortgeschrittene gastrointestinale Krebsarten und analysiert Proteinziele wie HER2, RET, MHC-II, EGFR, TROP2, AKT und ERK. Finanzielle Details wurden nicht bekannt gegeben; dennoch stellt dies eine der bedeutendsten Forschungsdienstleistungskooperationen von Ignite dar.
- First precision oncology trial using functional proteomics for pan-tumor treatment decisions
- Analysis capability of up to 600 tumor samples for comprehensive biomarker data
- Expected to contribute meaningfully to company's 2025 revenue
- One of the most significant research services collaborations for Ignite Proteomics to date
- Financial terms of the collaboration not disclosed
- Limited to primarily gastrointestinal cancers in late stages
Insights
Ignite's deal with Inova brings revenue while validating their protein analysis technology in precision oncology, advancing their diagnostic market position.
This collaboration represents a strategic advancement for Ignite Proteomics and its parent IMAC Holdings by applying their Reverse Phase Protein Array (RPPA) technology in a clinical decision-making context. The agreement to analyze up to 600 tumor samples from late-stage cancer patients positions Ignite in the growing precision oncology market, where traditional genomics approaches are being complemented by proteomics data.
The partnership with Inova Health's Molecular Tumor Board creates a real-world clinical validation of Ignite's technology, potentially establishing their RPPA platform as a valuable tool for oncologists facing difficult treatment decisions. By analyzing specific protein and phospho-protein targets like HER2, RET, and EGFR, Ignite's technology addresses a critical gap in current cancer diagnostics - directly measuring the activity of protein drug targets rather than just their genetic expression.
While financial specifics weren't disclosed, the press release indicates this is one of Ignite's "most significant research services collaborations" that will contribute meaningfully to 2025 revenue. For IMAC Holdings, this represents potential diversification of revenue streams through their Ignite subsidiary and validation in the competitive cancer diagnostics market. The focus on late-stage gastrointestinal cancers provides a defined initial application, with potential to expand to other cancer types if successful. This collaboration demonstrates commercial traction for Ignite's technology in a clinical setting beyond pure research applications.
The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study
Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB: BACK), today announced that it has entered into a research collaboration with Inova Health to apply Ignite鈥檚 Reverse Phase Protein Array (RPPA) technology to tumor samples from patients, primarily with late-stage gastrointestinal cancers. The data provided from the analysis by RPPA will be used to help oncologists select from multiple treatment options where no current guidance is available.
Under the agreement, Ignite will analyze up to 600 tumor samples to generate actionable biomarker data across a panel of cancer-relevant drug target proteins, including HER2, RET, MHC-II, EGFR, TROP2, AKT, ERK, and others. Results will be provided to Inova鈥檚 Molecular Tumor Board to assess therapy response and resistance in gastrointestinal cancers based on specific protein or phosphor-protein levels.
鈥淭his collaboration with Inova underscores the expanding applications of our RPPA technology in solid tumors,鈥� said Faith Zaslavsky, President and CEO of Ignite Proteomics. 鈥淏y partnering with Inova鈥檚 Molecular Tumor Board, we aim to accelerate precision medicine approaches for patients with gastrointestinal cancers.鈥�
鈥淎t Inova, our mission is to bring the most advanced science into the clinic for patients who have run out of standard options鈥� said Timothy Cannon, MD, Director of the Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova. 鈥淭his collaboration gives our Molecular Tumor Board a new lens鈥攁 direct measure of the activity of the protein drug targets themselves that you cannot get from genomics analysis. This key missing information could better help guide treatment decisions in late-stage cancers, where every additional month of effective therapy matters.鈥�
While specific financial terms were not disclosed, the agreement represents one of the most significant research services collaborations to date for Ignite Proteomics and is expected to contribute meaningfully to the Company鈥檚 2025 revenue.
About Ignite Proteomics
Ignite Proteomics, a subsidiary of IMAC Holdings, delivers pathway鈥憀evel protein analytics to guide precision oncology. Operating a CLIA鈥慶ertified, CAP鈥慳ccredited laboratory, Ignite's clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from minute biopsy material, with many more in research stages, enabling oncologists and drug developers to match patients with the most effective targeted and immune therapies.
Forward鈥�Looking Statements
This press release contains forward鈥憀ooking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected scope, timeline, and potential outcomes of the collaboration with Inova. Forward鈥憀ooking statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Important factors that could affect actual results include, among others, the successful completion of the research project, and the validity and reproducibility of study data. Except as required by law, IMAC Holdings undertakes no obligation to update forward鈥憀ooking statements contained herein to reflect events or circumstances after the date of this release.
Investor & Media Contact
|
FAQ
What is the purpose of the collaboration between Ignite Proteomics (BACK) and Inova Health?
How many tumor samples will Ignite Proteomics (BACK) analyze in the Inova Health study?
Which protein targets will be analyzed in the Ignite Proteomics (BACK) and Inova Health study?
How will this collaboration impact Ignite Proteomics' (BACK) revenue in 2025?
What types of cancers will be studied in the Ignite Proteomics (BACK) and Inova Health collaboration?
